Home/Filings/4/0001819790-25-000045
4//SEC Filing

Whitfield Dianne C. 4

Accession 0001819790-25-000045

CIK 0001819790other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 9:39 PM ET

Size

11.6 KB

Accession

0001819790-25-000045

Insider Transaction Report

Form 4
Period: 2025-03-15
Whitfield Dianne C.
Chief Human Resources Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-157,24814,497 total
    Common Stock (7,248 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-157,17521,527 total
    Common Stock (7,175 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-154,4624,463 total
    Common Stock (4,462 underlying)
  • Exercise/Conversion

    Common Stock

    2025-03-15+18,88553,066 total
Footnotes (5)
  • [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
  • [F2]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.
  • [F4]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
  • [F5]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001839516

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:39 PM ET
Size
11.6 KB